- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03630614
Randomized Trial of Electronic Cigarettes With or Without Nicotine in Smoking Cessation. (ECSMOKE)
A Randomized, Placebo Controlled, Double Blind, Double Dummy, Multicenter Trial Comparing Electronic Cigarettes With Nicotine to Varenicline and to Electronic Cigarettes Without Nicotine.
Background:
Electronic cigarettes (EC) mainly containing nicotine (88-95 % of users) are widely and growingly used worldwide. It is estimated that there were 1.7 million daily users in France in 2016. Although the number of publications about its use is increasing exponentially, there are no evidence based, unbiased, head-to-head comparison data about its efficacy as an aid to smoking cessation. As of today, only two head-to-head randomized studies have been published, both reported negative results at the main endpoint but they used first and second generation EC delivering nicotine with low or unknown bioavailability. Recent EC deliver nicotine with largely improved bioavailability.
One of the randomized studies compared EC with and without nicotine to nicotine patch and reported similar smoking cessation rate at main outcome. However, there is no published, double blind study comparing EC use with a well-studied, licensed smoking cessation medication.
Superiority of EC with nicotine compared to EC without nicotine and to a reference smoking cessation medication while collecting also straightforward information about safety, would allow proposing EC with nicotine to the large population of smokers who intend to quit and situate it among the approved smoking cessation treatments.
The clinical study's hypothesis:
EC containing nicotine can be considered as a nicotine replacement therapy having, probably, a better bioavailability of nicotine than the marketed pharmaceutical NRTs, first line medications of smoking cessation. It is therefore of interest to compare EC containing nicotine to EC without nicotine but also to a reference medication with demonstrated efficacy in smoking cessation. We hypothesize that EC with nicotine provides a higher smoking abstinence rate than EC without nicotine and may be as good as varenicline, our reference medication.
Study Overview
Status
Detailed Description
This is a randomized, placebo controlled, multicenter, double dummy, parallel groups, phase III type pivotal trial.
Included participants are randomly assigned to one of the 3 groups:
A) Control group: Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline: placebo condition B) Experimental group: Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline: ECwN condition C) Reference group: ECwoN plus varenicline tablets: varenicline condition Ratio: A:B:C= 1:3:3 Each participant uses an EC and 2x2 tablets per day. Group allocation is stratified by age at cut off of 45 years.
Enrolment is initiated by two ways:
• Potential participants aware of the study register at the study's recruitment website; call in or send an email followed by a phone screen. The screening starts with the participant's information about the study's aims, constraints, benefits and risks. A maximum one week delay of reflection is allowed if the potential participant is asking for a delay to sign his/her consent form.
After screening, an appointment for the inclusion visit is provided at the closest investigation center.
• Referred or self-referred potential participants consulting for smoking cessation are proposed an inclusion visit.
The participant is informed that in this study, the smoking cessation shall occur within 15 days following the signature of the written consent.
Baseline visit = inclusion visit = V0 The Inclusion visit can immediately follow the screening visit if the participant does not need time for reflection.
The investigator checks the inclusion and exclusion criteria and if the participant is conform to them, the investigator collects informed written consent from the participant and he/she is included in the trial. The randomization can immediately follow the inclusion.
A target quit date (TQD) is defined together with the participant. The TQD defines the date when the randomized participant stops smoking. This is the starting date of the post-quit period. Start of treatment should occur within 7 days after the randomization visit.
All treatments are launched one week before the TQD. During this period smoking conventional cigarettes is allowed.
Follow-up visits : Visit 1 to Visit 6 Target quit date (TQD) should occur between 7 and 15 days after randomization. The first post-quit date visit (Visit 1)is at Week 2 after TQD i.e. 3 weeks after treatment initiation = Day 21 after treatment initiation.
Visit 2 is at Week 4 after TQD i.e. 5 weeks after treatment initiation = Day 35 after treatment initiation.
Visit 3 is at Week 8 after TQD i.e. 9 weeks after treatment initiation = Day 63 after treatment initiation.
Visit 4 is at Week 10 after TQD i.e. 11 weeks after treatment initiation = Day 77 after treatment initiation.
Visit 5 is at Week 12 after TQD i.e. 13 weeks after treatment initiation = Day 91 after treatment initiation.
Visit 6 is at Week 24 after TQD i.e. 25 weeks after treatment initiation = Day 175 after treatment initiation.
The visits should be realized +/- 5 days with respect to the planned date of the visits.
End of study visit The end of research visit is the Visit 6, at week 24 after TQD. This visit is identical to the previous follow up visits.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Ivan BERLIN, M.D., Ph.D.
- Phone Number: +33 1 42 16 16 78
- Email: ivan.berlin@aphp.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Groupe Hospitalier Pitie-Salpetriere
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Smokers smoking at least 10 cigarettes/day (factory made or roll-your-own) in the past year
- Aged 18 to 70 years
- Motivated to quit defined as a score > 5 on a visual rating scale ranging from 0 (not motivated at all) to 10 (extremely motivated)
- Signed written informed consent
- Understanding and speaking French
- Women of childbearing age can be included if they use an effective contraceptive method: either hormonal contraception or an intrauterine device started at least one month before the first research visit
- Individual affiliated to a health insurance system as defined by the sponsor (except Aide Médicale d'État =AME)
- Previous failure of nicotine replacement therapy for smoking cessation
Exclusion Criteria:
- any unstable disease condition within the last 3 months defined by the investigator as major change in symptoms or treatments such as 1.1.recent myocardial infarction, 1.2.unstable or worsening angina 1.3.severe cardiac arrhythmia 1.4.unstable or uncontrolled arterial hypertension 1.5.recent stroke 1.6.cerebrovascular disease 1.7.obliterative peripheral arterial disease 1.8.cardiac insufficiency 1.9.diabetes 1.10.hyperthyroidism 1.11.pheochromocytoma 1.12.severe hepatic insufficiency 1.13.history of seizures 1.14.severe depression 1.15.chronic obstructive pulmonary disease (COPD)
- any life threatening condition with life-expectancy of less than 3 months
- alcohol use disorder defined as a score ≥ 10 on the AUDIT-C questionnaire
- abuse of or dependence on illegal drugs in the last 6 months revealed by the medical history
- regular use of tobacco products other than cigarettes
- current or previous (last 6 months) use of electronic cigarette
- pregnant women
- breastfeeding women
- protected adults
- current or past 3 months participation in another interventional research
- current or past (last 3 months) use of smoking cessation medication such as varenicline, bupropion, nicotine replacement therapies
- known lactose intolerance (placebo tablets contain lactose)
- hypersensitivity to the active substance or to any of the excipients
- known severe renal failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Electronic cigarette condition
Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
|
The ECwN group use EC liquids containing 12 mg/mL of nicotine.
Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet.
Posology of varenicline or its placebo follows varenicline's monograph.
Other Names:
|
ACTIVE_COMPARATOR: Varenicline condition
Reference group: Electronic cigarette without nicotine (ECwoN) plus active varenicline tablets
|
The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes. EC device: Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid. Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph.
Other Names:
|
PLACEBO_COMPARATOR: Placebo condition
Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
|
The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL). Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Continuous smoking abstinence rate
Time Frame: Weeks 9 to 12
|
Abstinence from conventional/combustible cigarettes during the last 4 weeks (weeks 9 to 12) of the treatment period of 3 months defined at Visit 4 AND Visit 5 as self-report of no smoking during the previous 2 weeks confirmed by expired air CO ≤ 8 ppm.
|
Weeks 9 to 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).
Time Frame: From randomisation up to end of study (Week 24 after target quit date).
|
The safety profile of electronic cigarette with nicotine comparatively to electronic cigarettes without nicotine and varenicline
|
From randomisation up to end of study (Week 24 after target quit date).
|
Point prevalence abstinence rate: 7-day smoking abstinence at each visit.
Time Frame: From randomisation up to end of study (Week 24 after target quit date).
|
From randomisation up to end of study (Week 24 after target quit date).
|
|
Time to relapse to smoking after the predefined quit day.
Time Frame: From randomisation up to end of study (Week 24 after target quit date).
|
From randomisation up to end of study (Week 24 after target quit date).
|
|
Change in cigarettes/day consumption
Time Frame: From randomisation up to end of study (Week 24 after target quit date).
|
From randomisation up to end of study (Week 24 after target quit date).
|
|
French Tobacco Craving Questionnaire of 12 items (FTCQ-12)
Time Frame: From randomisation up to end of study (Week 24 after target quit date).
|
Change in craving for tobacco
|
From randomisation up to end of study (Week 24 after target quit date).
|
Minnesota Nicotine Withdrawal Scale
Time Frame: From randomisation up to end of study (Week 24 after target quit date).
|
Change in tobacco withdrawal symptoms
|
From randomisation up to end of study (Week 24 after target quit date).
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P150952J
- 2017-003588-37 (EUDRACT_NUMBER)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
The University of Hong KongNot yet recruitingSmoking Cessation Counseling Ability | Smoking Cessation Counseling PracticeHong Kong
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
Clinical Trials on Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
-
Weill Medical College of Cornell UniversityTerminated
-
Christian CasanovaCompletedElectronic Cigarette Use | Retina; ChangeCanada
-
University of California, San FranciscoNational Cancer Institute (NCI); Food and Drug Administration (FDA)CompletedAdverse Effect of Other Agents Primarily Affecting the Cardiovascular System, Initial EncounterUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA)RecruitingCurrent Every Day Smoker | Cigarette SmokerUnited States
-
University of Kansas Medical CenterRecruiting
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedNicotine DependenceUnited States
-
UConn HealthCompleted